<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01652872</url>
  </required_header>
  <id_info>
    <org_study_id>20110226</org_study_id>
    <nct_id>NCT01652872</nct_id>
  </id_info>
  <brief_title>Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease</brief_title>
  <acronym>START-CKD</acronym>
  <official_title>Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3, multicenter, randomized, double-blind, parallel group study. Anemic subjects with
      chronic kidney disease (CKD) and not on dialysis will be randomized 1:1 to 1 of 2 dosing
      strategies to evaluate the proportion of subjects receiving at least one red blood cell (RBC)
      transfusion. In the haemoglobin (Hb)-based titration group, darbepoetin alfa doses will be
      titrated to maintain Hb ≥ 10.0 grams/deciliter (g/dL). In the fixed dose group, subjects will
      receive a fixed dose of darbepoetin alfa. Treatment group, darbepoetin alfa doses, and
      protocol specified Hb concentrations will be blinded. Subjects will be followed for
      approximately 2 years from the date of randomization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a phase 3, multicenter, randomized, double-blind, parallel group study designed
      to describe the benefits and potential risks of a new treatment strategy using a fixed dose
      of darbepoetin alfa in subjects with CKD and not on dialysis. Anemic subjects without recent
      use of an erythropoiesis stimulating agent (ESA) will be randomly allocated 1:1 to treatment
      with a fixed dose of darbepoetin alfa or to treatment with darbepoetin alfa using a Hb-based
      titration strategy, which has been the conventional dosing strategy. In the Hb-based
      titration group, darbepoetin alfa doses will be titrated to maintain Hb ≥ 10.0 g/dL. This
      study aims to estimate the incidence of RBC transfusions (administered as deemed clinically
      necessary) in each group and the difference in incidence of RBC transfusions between the 2
      groups. In addition, multiple aspects, such as cumulative darbepoetin alfa dose, total number
      of units of transfusions, Hb concentration, Hb-related parameters (eg, Hb variability,
      excursions, rate of change), and adverse (eg, cardiovascular) events, will also be considered
      in order to determine a preferred dosing regimen. Treatment group, darbepoetin alfa doses,
      and protocol specified Hb concentrations will be blinded to the investigator, subjects and
      study team. Subjects will be followed for approximately 2 years from the date of
      randomization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2012</start_date>
  <completion_date type="Actual">October 19, 2017</completion_date>
  <primary_completion_date type="Actual">October 19, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in Receipt of 1 or More RBC Transfusions</measure>
    <time_frame>From randomization until the end of study, up to week 101.</time_frame>
    <description>The percentage of participants receiving at least 1 RBC transfusion during the evaluation period was recorded for each treatment group. The evaluation period began from the date of randomization, and participants were censored at the last dose of investigational product plus 3 months or end of study, whichever was earlier (on-treatment approach).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Units of RBC Transfused</measure>
    <time_frame>From randomization until the end of study, up to week 101.</time_frame>
    <description>The total number of units of RBC transfused per participant during the evaluation period was recorded for each treatment group. The evaluation period began from the date of randomization, and participants were censored at the last dose of investigational product plus 3 months or end of study, whichever was earlier (on-treatment approach). The mean total number of RBC units transfused per participant is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First RBC Transfusion</measure>
    <time_frame>From randomization until the end of study, up to week 101.</time_frame>
    <description>Time to first RBC transfusion during the evaluation period was recorded for each treatment group. The evaluation period began from the date of randomization, and participants were censored at the last dose of investigational product plus 3 months or end of study, whichever was earlier (on-treatment approach). The time to first RBC transfusion is presented using Kaplan-Meier (KM) estimates at 6, 12, 18, and 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Achieved Hb Concentration While Receiving Investigational Product</measure>
    <time_frame>From week 13 until the end of study, up to week 101.</time_frame>
    <description>Average achieved Hb concentration while receiving investigational product was recorded as mean Hb using the area under the curve (AUC) method for each treatment group. The AUC of Hb was calculated according to the trapezoidal method, standardized as daily AUC. Participants with available Hb values from study day 85 (week 13) to the last dose date were included in the calculation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Cumulative Dose of Darbepoetin Alfa Per 4 Weeks</measure>
    <time_frame>From randomization until the end of study, up to week 101.</time_frame>
    <description>Cumulative doses of darbepoetin alfa adjusted for investigation product exposure time (e.g. mean cumulative darbepoetin alfa dose per 4 weeks) were calculated for each treatment group using the total cumulative dose during the study divided by total number of weeks dosed then multiplied by 4. The geometric mean cumulative dose is presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">756</enrollment>
  <condition>Anemia in Chronic Kidney Disease Patients Not on Dialysis</condition>
  <arm_group>
    <arm_group_label>Hb-Based Titration Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received darbepoetin alfa as a subcutaneous (SC) injection once every 4 weeks (Q4W) for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb rate of rise (ROR), and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 micrograms/kilogram (mcg/kg) and the protocol specified doses ranged from 10 to 300 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96 week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was &gt; 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to &lt; 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.</description>
    <arm_group_label>Fixed Dose Group</arm_group_label>
    <arm_group_label>Hb-Based Titration Group</arm_group_label>
    <other_name>Aranesp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.</description>
    <arm_group_label>Fixed Dose Group</arm_group_label>
    <arm_group_label>Hb-Based Titration Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Clinical history of advanced CKD not on dialysis with at least 1 historic estimated
             glomerular filtration rate (eGFR) &lt; 45.0 mL/mi)/1.73 m2 at least 12 weeks prior to
             screening

          -  Not currently receiving dialysis with an eGFR &lt; 45.0 mL/min/1.73m2, per the central
             laboratory during screening

          -  Chronic anemia due to renal failure

          -  Two Hb concentrations &lt; 10.0 g/dL, at least 2 weeks apart during screening using the
             modified Hb point of care (POC) device

          -  Iron replete, defined as a transferrin saturation (TSAT) ≥ 20% and a ferritin ≥ 100
             ng/mL, per the central laboratory during screening

          -  Vitamin B12 and folate replete, defined as a vitamin B12 level &gt; 180 pg/mL and a
             folate concentration &gt; 7 nmol/L, per the central laboratory during screening

          -  Clinically stable in the opinion of the investigator

          -  Subject has provided written informed consent

        Key Exclusion Criteria:

          -  Systemic hematologic disease (eg, sickle cell anemia, myelodysplastic syndrome,
             hematologic malignancy)

          -  Current or prior malignancy within 5 years of screening, with the exception of
             non-melanoma skin cancers and cervical intraepithelial neoplasia

          -  Treatment for any malignancy (eg, radiation, chemotherapy, hormone therapy, or
             biologics) within 5 years of screening, with the exception of locally excised
             non-melanoma skin cancer or cervical intraepithelial neoplasia

          -  Female subject not willing to use highly effective methods of birth control during
             treatment and for 4 weeks after the end of treatment

          -  Subject is pregnant or breast feeding, or might become pregnant during the study or
             within 4 weeks after the end of treatment

          -  Currently receiving intravenous (IV) antibiotics for treatment of an active infection

          -  Known Human Immunodeficiency Virus (HIV) positive

          -  Currently receiving systemic immunosuppressive therapy with the exception of
             prednis(ol)one ≤ 10 mg per day (or the steroid equivalent)

          -  History of any organ transplant

          -  Currently enrolled in another interventional study (eg, studies which require medical
             device use or drug therapy or with protocol required procedures), or less than 4 weeks
             since ending another interventional study(s) or receiving investigational agent(s)

          -  Known neutralizing anti-erythropoietic protein antibodies

          -  Known sensitivity to any of the products to be administered during dosing

          -  Previously enrolled in this study

          -  Not expected to be available for protocol required study visits or procedures to the
             best of the subject and investigator's knowledge

          -  Subject has any kind of disorder that, in the opinion of the investigator, may
             compromise the ability of the subject to give written informed consent and/or comply
             with all required study procedures

          -  Occurrence of stroke or myocardial infarction (MI) within 24 weeks of screening

          -  Receipt of RBC transfusion within 8 weeks of screening

          -  Occurrence of seizure, clinically relevant active bleeding (eg, gastrointestinal [GI]
             bleed) or any hospitalization within 8 weeks of screening

          -  Receipt of any IV iron therapy within 4 weeks of screening

          -  Changes in oral iron therapy within 4 weeks of screening

          -  Receipt of ESA therapy within 4 weeks of screening

          -  Diagnosis or treatment of malignancy, with the exception of non-melanoma skin cancers
             and cervical intraepithelial neoplasia during screening

          -  Receipt of ESA therapy, RBC transfusions, IV iron therapy during screening

          -  Changes in oral iron therapy during screening

          -  Occurrence of stroke, MI, seizure, clinically relevant active bleeding (eg, GI bleed),
             any hospitalization or outpatient surgery during screening

          -  Uncontrolled hypertension during screening. Defined in this study, as a mean systolic
             blood pressure &gt; 140 mmHg at both screening visits, or a mean systolic blood pressure
             &gt;/= 160 mmHg at any screening visit, or a mean diastolic blood pressure &gt;/= 90 mmHg at
             any screening visit.

          -  Expected or scheduled change in oral iron therapy or receipt of IV iron therapy within
             4 weeks after randomization

          -  Expected or scheduled receipt of a RBC transfusion within 8 weeks after randomization

          -  Expected or scheduled organ transplant within 24 weeks after randomization

          -  Expected or scheduled initiation of dialysis within 24 weeks after randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85395</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bell Gardens</city>
        <state>California</state>
        <zip>90201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cudahy</city>
        <state>California</state>
        <zip>90201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Centro</city>
        <state>California</state>
        <zip>92243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Granada Hills</city>
        <state>California</state>
        <zip>91344</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <zip>90262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yuba City</city>
        <state>California</state>
        <zip>95991</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arvada</city>
        <state>Colorado</state>
        <zip>80002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westminster</city>
        <state>Colorado</state>
        <zip>80031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Haven</city>
        <state>Connecticut</state>
        <zip>06473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hudson</city>
        <state>Florida</state>
        <zip>34667</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>32250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Summerfield</city>
        <state>Florida</state>
        <zip>34491</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canton</city>
        <state>Georgia</state>
        <zip>30114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Indiana</state>
        <zip>47201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-2998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Natchitoches</city>
        <state>Louisiana</state>
        <zip>71457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruston</city>
        <state>Louisiana</state>
        <zip>71270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rockport</city>
        <state>Maine</state>
        <zip>04856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <zip>20745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Framingham</city>
        <state>Massachusetts</state>
        <zip>01702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <state>Massachusetts</state>
        <zip>02360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <zip>48640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southgate</city>
        <state>Michigan</state>
        <zip>48195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Mississippi</state>
        <zip>39705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Platte</city>
        <state>Nebraska</state>
        <zip>69101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <zip>14127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosedale</city>
        <state>New York</state>
        <zip>11422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <zip>28117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poland</city>
        <state>Ohio</state>
        <zip>44514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Willoughby Hills</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roseburg</city>
        <state>Oregon</state>
        <zip>97471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>Tennessee</state>
        <zip>38401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dyersburg</city>
        <state>Tennessee</state>
        <zip>38024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>Texas</state>
        <zip>75402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>75904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mechanicsville</city>
        <state>Virginia</state>
        <zip>23116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Silverdale</city>
        <state>Washington</state>
        <zip>98383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bluefield</city>
        <state>West Virginia</state>
        <zip>24701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caguas</city>
        <zip>00725</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ponce</city>
        <zip>00717</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 7, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2012</study_first_posted>
  <results_first_submitted>October 11, 2018</results_first_submitted>
  <results_first_submitted_qc>October 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2018</results_first_posted>
  <last_update_submitted>November 21, 2018</last_update_submitted>
  <last_update_submitted_qc>November 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>kidney disease</keyword>
  <keyword>renal failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 16, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT01652872/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 16, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT01652872/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Anemic participants with chronic kidney disease and not on dialysis (CKD-ND) were enrolled at 126 study centers in the United States, from 30 July 2012 to 19 October 2017. The on-study duration was approximately 2 years, comprising of a 2- to 4-week screening period, a 96-week treatment period and a 4-week follow up period.</recruitment_details>
      <pre_assignment_details>Participants were randomized in a 1:1 ratio to 1 of 2 darbepoetin alfa dosing strategies (hemoglobin [Hb]-based titration group or fixed dose group). Randomization was stratified by red blood cell (RBC) transfusion received within 12 months prior to randomization (yes/no) and site practice setting (nephrology/non-nephrology).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Hb-Based Titration Group</title>
          <description>Participants received darbepoetin alfa as a subcutaneous (SC) injection once every 4 weeks (Q4W) for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb rate of rise (ROR), and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 grams/deciliter (g/dL) or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 micrograms/kilogram (mcg/kg) and the protocol specified doses ranged from 10 to 300 mcg.</description>
        </group>
        <group group_id="P2">
          <title>Fixed Dose Group</title>
          <description>Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96-week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was &gt; 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to &lt; 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="377"/>
                <participants group_id="P2" count="379"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Investigational Product</title>
              <participants_list>
                <participants group_id="P1" count="377"/>
                <participants group_id="P2" count="377"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hb-Based Titration Group</title>
          <description>Participants received darbepoetin alfa as a SC injection, Q4W for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb ROR, and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
        </group>
        <group group_id="B2">
          <title>Fixed Dose Group</title>
          <description>Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96-week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was &gt; 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to &lt; 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="377"/>
            <count group_id="B2" value="379"/>
            <count group_id="B3" value="756"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.2" spread="13.5"/>
                    <measurement group_id="B2" value="69.5" spread="13.1"/>
                    <measurement group_id="B3" value="69.4" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>18 - 64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="263"/>
                  </measurement_list>
                </category>
                <category>
                  <title>65 - 74 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>75 - 84 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="202"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=85 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="441"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="569"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="435"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed race/Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous RBC transfusions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="285"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in Receipt of 1 or More RBC Transfusions</title>
        <description>The percentage of participants receiving at least 1 RBC transfusion during the evaluation period was recorded for each treatment group. The evaluation period began from the date of randomization, and participants were censored at the last dose of investigational product plus 3 months or end of study, whichever was earlier (on-treatment approach).</description>
        <time_frame>From randomization until the end of study, up to week 101.</time_frame>
        <population>The full analysis set included all randomized participants who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Hb-Based Titration Group</title>
            <description>Participants received darbepoetin alfa as a SC injection, Q4W for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb ROR, and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose Group</title>
            <description>Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96-week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was &gt; 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to &lt; 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Receipt of 1 or More RBC Transfusions</title>
          <description>The percentage of participants receiving at least 1 RBC transfusion during the evaluation period was recorded for each treatment group. The evaluation period began from the date of randomization, and participants were censored at the last dose of investigational product plus 3 months or end of study, whichever was earlier (on-treatment approach).</description>
          <population>The full analysis set included all randomized participants who received at least 1 dose of investigational product.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.40" lower_limit="20.07" upper_limit="28.74"/>
                    <measurement group_id="O2" value="24.14" lower_limit="19.82" upper_limit="28.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.39</ci_lower_limit>
            <ci_upper_limit>5.85</ci_upper_limit>
            <estimate_desc>Difference is fixed dose - titration.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.998</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.776</ci_lower_limit>
            <ci_upper_limit>1.285</ci_upper_limit>
            <estimate_desc>A risk ratio &lt; 1.0 indicates a lower event rate for the fixed dose group relative to Hb-based titration group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Units of RBC Transfused</title>
        <description>The total number of units of RBC transfused per participant during the evaluation period was recorded for each treatment group. The evaluation period began from the date of randomization, and participants were censored at the last dose of investigational product plus 3 months or end of study, whichever was earlier (on-treatment approach). The mean total number of RBC units transfused per participant is presented.</description>
        <time_frame>From randomization until the end of study, up to week 101.</time_frame>
        <population>The full analysis set included all randomized participants who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Hb-Based Titration Group</title>
            <description>Participants received darbepoetin alfa as a SC injection, Q4W for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb ROR, and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose Group</title>
            <description>Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96-week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was &gt; 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to &lt; 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Units of RBC Transfused</title>
          <description>The total number of units of RBC transfused per participant during the evaluation period was recorded for each treatment group. The evaluation period began from the date of randomization, and participants were censored at the last dose of investigational product plus 3 months or end of study, whichever was earlier (on-treatment approach). The mean total number of RBC units transfused per participant is presented.</description>
          <population>The full analysis set included all randomized participants who received at least 1 dose of investigational product.</population>
          <units>Units of transfused RBC</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" lower_limit="0.53" upper_limit="0.89"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.65" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Stratified by RBC transfusion received within 12 months prior to randomization (yes/no) and site practice setting (nephrology/non-nephrology) and accounting for participant exposure time.</non_inferiority_desc>
            <param_type>Least Squares Mean (LSM) Ratio</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
            <estimate_desc>Least Squares Mean (LSM) ratio is fixed dose relative to titration.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First RBC Transfusion</title>
        <description>Time to first RBC transfusion during the evaluation period was recorded for each treatment group. The evaluation period began from the date of randomization, and participants were censored at the last dose of investigational product plus 3 months or end of study, whichever was earlier (on-treatment approach). The time to first RBC transfusion is presented using Kaplan-Meier (KM) estimates at 6, 12, 18, and 24 months.</description>
        <time_frame>From randomization until the end of study, up to week 101.</time_frame>
        <population>The full analysis set included all randomized participants who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Hb-Based Titration Group</title>
            <description>Participants received darbepoetin alfa as a SC injection, Q4W for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb ROR, and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose Group</title>
            <description>Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96-week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was &gt; 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to &lt; 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First RBC Transfusion</title>
          <description>Time to first RBC transfusion during the evaluation period was recorded for each treatment group. The evaluation period began from the date of randomization, and participants were censored at the last dose of investigational product plus 3 months or end of study, whichever was earlier (on-treatment approach). The time to first RBC transfusion is presented using Kaplan-Meier (KM) estimates at 6, 12, 18, and 24 months.</description>
          <population>The full analysis set included all randomized participants who received at least 1 dose of investigational product.</population>
          <units>Months</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KM estimates at month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.115"/>
                    <measurement group_id="O2" value="0.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KM estimates at month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.192"/>
                    <measurement group_id="O2" value="0.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KM estimates at month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.261"/>
                    <measurement group_id="O2" value="0.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KM estimates at month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.297"/>
                    <measurement group_id="O2" value="0.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>Hazard ratio is fixed dose relative to titration.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Achieved Hb Concentration While Receiving Investigational Product</title>
        <description>Average achieved Hb concentration while receiving investigational product was recorded as mean Hb using the area under the curve (AUC) method for each treatment group. The AUC of Hb was calculated according to the trapezoidal method, standardized as daily AUC. Participants with available Hb values from study day 85 (week 13) to the last dose date were included in the calculation.</description>
        <time_frame>From week 13 until the end of study, up to week 101.</time_frame>
        <population>The full analysis set included all randomized participants who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Hb-Based Titration Group</title>
            <description>Participants received darbepoetin alfa as a SC injection, Q4W for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb ROR, and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose Group</title>
            <description>Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96-week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was &gt; 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to &lt; 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Achieved Hb Concentration While Receiving Investigational Product</title>
          <description>Average achieved Hb concentration while receiving investigational product was recorded as mean Hb using the area under the curve (AUC) method for each treatment group. The AUC of Hb was calculated according to the trapezoidal method, standardized as daily AUC. Participants with available Hb values from study day 85 (week 13) to the last dose date were included in the calculation.</description>
          <population>The full analysis set included all randomized participants who received at least 1 dose of investigational product.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.71" spread="0.04"/>
                    <measurement group_id="O2" value="9.41" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Median of the difference</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
            <estimate_desc>Difference is fixed dose - titration.</estimate_desc>
            <other_analysis_desc>The 2-sided 95% confidence intervals were obtained using a non-parametric Wilcoxon rank-sum statistic.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Cumulative Dose of Darbepoetin Alfa Per 4 Weeks</title>
        <description>Cumulative doses of darbepoetin alfa adjusted for investigation product exposure time (e.g. mean cumulative darbepoetin alfa dose per 4 weeks) were calculated for each treatment group using the total cumulative dose during the study divided by total number of weeks dosed then multiplied by 4. The geometric mean cumulative dose is presented.</description>
        <time_frame>From randomization until the end of study, up to week 101.</time_frame>
        <population>The full analysis set included all randomized participants who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Hb-Based Titration Group</title>
            <description>Participants received darbepoetin alfa as a SC injection, Q4W for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb ROR, and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose Group</title>
            <description>Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96-week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was &gt; 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to &lt; 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Cumulative Dose of Darbepoetin Alfa Per 4 Weeks</title>
          <description>Cumulative doses of darbepoetin alfa adjusted for investigation product exposure time (e.g. mean cumulative darbepoetin alfa dose per 4 weeks) were calculated for each treatment group using the total cumulative dose during the study divided by total number of weeks dosed then multiplied by 4. The geometric mean cumulative dose is presented.</description>
          <population>The full analysis set included all randomized participants who received at least 1 dose of investigational product.</population>
          <units>mcg</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7" spread="2.7"/>
                    <measurement group_id="O2" value="30.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Median of the difference</param_type>
            <param_value>-22.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.1</ci_lower_limit>
            <ci_upper_limit>-18.1</ci_upper_limit>
            <estimate_desc>Difference is fixed dose - titration.</estimate_desc>
            <other_analysis_desc>The 2-sided 95% confidence intervals were obtained using a non-parametric Wilcoxon rank-sum statistic.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment Emergent Adverse Events were collected from randomization on study day 1 until 4 weeks after final dose of investigational product (up to 101 weeks).</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Hb-Based Titration Group</title>
          <description>Participants received darbepoetin alfa as a SC injection, Q4W for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb ROR, and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
        </group>
        <group group_id="E2">
          <title>Fixed Dose Group</title>
          <description>Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96-week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was &gt; 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to &lt; 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperprothrombinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Emphysematous pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Mycobacterium kansasii infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Streptococcal urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haematuria traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Acid base balance abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>ECG signs of myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Acidosis hyperchloraemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperinsulinaemic hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Metastatic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Thymoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pleural fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Dialysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diastolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="292" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="300" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hilar lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Aortic valve sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dilatation atrial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Left ventricular dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Mitral valve calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vascular malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperadrenalism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism secondary</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Secondary hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Astigmatism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cataract cortical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diabetic retinal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Eye allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypermetropia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ophthalmoplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Presbyopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Change of bowel habit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oesophageal food impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Parotid gland enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sluggishness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vaccination site bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blister infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chikungunya virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Coccidioidomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastric ulcer helicobacter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Genital candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Periorbital abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sebaceous gland infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal scratch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Eye contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nail avulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tooth avulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Traumatic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vaccination complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood iron decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood parathyroid hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood phosphorus increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood potassium abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood pressure abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Carbon dioxide decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Computerised tomogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Endoscopy gastrointestinal normal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Protein total increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Serum ferritin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Thyroid function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tuberculin test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal loss of weight</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Fluid imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperhomocysteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Iron overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Metabolic alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pseudohyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>CREST syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease-mineral and bone disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Enthesopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Limb mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Polymyositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Large intestine benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Renal haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cerebral small vessel ischaemic disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bladder mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Renal atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Breast ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cervical cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Paranasal sinus discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Snoring</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Drug reaction with eosinophilia and systemic symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hair texture abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Lentigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nail bed bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Purpura senile</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Carpal tunnel decompression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Catheter placement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Nephrostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Sinus operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Toe operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Blood pressure fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Diastolic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="377"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="377"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

